Global Net Revenue of $78.0 Million for the Third Quarter of 2026, an Increase of 13% Over the Prior Year, Supported by ...
Zomedica surpasses $9 million in quarterly revenue for the second quarter in a row while extending its record of consecutive ...
Net sales of $548 million rise 3% and also 3% at constant exchange rates (CER) Adjusted operating income margin of 30.4% ...
Ended quarter with approximately $901 million in cash, cash equivalents and investments, excluding $90 million in upfront ...
Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025 ...
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported ...
We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our ...
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE ...
STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 second quarter ended ...
ARC-20 data presented in October demonstrated the extraordinary opportunity for casdatifan to be a backbone treatment across ...
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on ...
Raises 2026 DAYBUE net sales guidance to $505–$520 million; narrows NUPLAZID range and total revenue range - Additional data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results